{"id":"escitalopram-aripiprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sexual dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking its reuptake transporter. Aripiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors. Together, they provide augmented antidepressant and anxiolytic effects with reduced side effects compared to either agent alone.","oneSentence":"This combination increases serotonin availability in the brain while blocking dopamine receptors to treat depression and related psychiatric conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:44.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Treatment-resistant depression (augmentation therapy)"}]},"trialDetails":[{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT02752542","phase":"PHASE4","title":"Personalized Indications for CBT and Antidepressants in Treating Depression","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2016-10-31","conditions":"Major Depressive Disorder, Persistent Depressive Disorder","enrollment":80},{"nctId":"NCT06054321","phase":"NA","title":"Psychopharmacotherapy for Depressive Patients","status":"RECRUITING","sponsor":"Chonnam National University Hospital","startDate":"2022-08-03","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT05389046","phase":"NA","title":"Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia","status":"UNKNOWN","sponsor":"Peking University","startDate":"2022-08-15","conditions":"Outpatients / Inpatients With Depression","enrollment":252},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT01123707","phase":"PHASE3","title":"To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-11-18","conditions":"Major Depressive Disorder (MDD)","enrollment":173},{"nctId":"NCT01111565","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-10-04","conditions":"Major Depressive Disorder (MDD)","enrollment":137},{"nctId":"NCT01111552","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-29","conditions":"Major Depressive Disorder (MDD)","enrollment":237},{"nctId":"NCT01111539","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-13","conditions":"Major Depressive Disorder (MDD)","enrollment":211},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT04234776","phase":"PHASE4","title":"Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2018-04-03","conditions":"Depressive Disorder","enrollment":88},{"nctId":"NCT01655706","phase":"PHASE3","title":"Canadian Biomarker Integration Network for Depression Study","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2012-04-23","conditions":"Major Depressive Disorder","enrollment":211},{"nctId":"NCT00953745","phase":"NA","title":"Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":43},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT02191358","phase":"","title":"YouScript IMPACT Registry","status":"COMPLETED","sponsor":"Genelex Corporation","startDate":"2014-10","conditions":"Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation","enrollment":800},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT00361790","phase":"PHASE1","title":"Aripiprazole and Lexapro Drug Interaction Study","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-08","conditions":"Healthy","enrollment":25},{"nctId":"NCT00608543","phase":"PHASE4","title":"Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2005-10","conditions":"Major Depressive Disorder","enrollment":17},{"nctId":"NCT00556140","phase":"PHASE3","title":"The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-06","conditions":"Psychotic Depression","enrollment":16},{"nctId":"NCT01488266","phase":"NA","title":"Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder","status":"UNKNOWN","sponsor":"Korea University","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":90},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lexapro, abilify"],"phase":"marketed","status":"active","brandName":"Escitalopram+Aripiprazole","genericName":"Escitalopram+Aripiprazole","companyName":"Ministry of Health & Welfare, Korea","companyId":"ministry-of-health-welfare-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination increases serotonin availability in the brain while blocking dopamine receptors to treat depression and related psychiatric conditions. Used for Major depressive disorder, Treatment-resistant depression (augmentation therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}